Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Goat anti-human IgG (γ-chain specific), (biotin conjugate)

ALX-211-502-C100 100 µg 150.00 USD
Do you need bulk/larger quantities?
A frequent cause of high background staining is due to non-specific binding of secondary antibodies. High quality secondary antibodies are crucial to obtaining good staining of targets that are normally harder to detect, for example due to low expression levels. Interference caused by endogenous immunoglobulins can also result in poor detection. Secondary antibodies specifically adsorbed against cross-reacting immunoglobulins will enhance results. ALX-211-502 is recommended for use with select ALEXIS recombinant fusion proteins containing the Fc portion of human IgG.

Product Specification

Immunogen:Human IgG.
Species reactivity:Human
Specificity:Recognizes the heavy chain of human IgG.
Applications:ELISA, Flow Cytometry, ICC, IHC (FS), IHC (PS), WB
Application Notes:Use with a streptavidin detection system.
Purity Detail:Purified by affinity chromatography on human IgG covalently linked to agarose. Cross-adsorbed with human IgM, IgD and IgA. Cross-reactivity with IgG from other species has not been evaluated.
Formulation:Liquid. In PBS, pH 7.4, containing 0.1% sodium azide.
Use/Stability:For increased long-term stability, add 40% glycerol to aliquots prior to freezing at -20°C.
Handling:Protect from light. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Shipping:Shipped on Blue Ice
Short Term Storage:+4°C
Long Term Storage:-20°C

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
IgG Secondary antibody
By catalog section:


Technical Service
Customer Service

Related Literature

Technical Posters
Disease-Associated Stress Signaling
Disease-Associated Stress Signaling
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,